Upregulation of PTX3 gene expression was observed associated to a stromal signature in ovarian cancer (116), and has been described in aggressive breast cancer and distant bone metastases (117–119), anaplastic thyroid carcinoma (120), soft tissue liposarcoma (121), prostate cancer (122), and glioblastoma (123). This evidence concerns the gene PTX3 and breast carcinoma.